Consensus Insmed Incorporated

Equities

INSM

US4576693075

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-18 pm EDT			5-day change	1st Jan Change
24.8 ^USD	-5.27%		-13.17%	-19.97%

Apr. 11	Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	MT
Mar. 27	Insmed Incorporated to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference	CI

Evolution of the average Target Price on Insmed Incorporated

Price target over the last 5 years

History of analyst recommendation changes

c53f.o49xEyBEvYBDmHhYyHtK8VRzO0OZX2f3YdgUn3J63CI.7b4CfA0WzbUM8wAxjC1zri4SbTSqLCGnJu0k6QhCjHGTzS57eiPU8getLQ~0c3292b670cf59b09d4455ad493c5107

Analyst Recommendations on Insmed Incorporated

Barclays Adjusts Price Target on Insmed to $40 From $37, Maintains Overweight Rating	Apr. 11	MT
UBS Initiates Coverage on Insmed With Buy Rating, $46 Price Target	Feb. 27	MT
Wolfe Research Starts Insmed With Outperform Rating, $42 Price Target	Feb. 15	MT
Mizuho Raises Price Target on Insmed to $35 From $33, Maintains Buy Rating	23-10-27	MT
Cantor Fitzgerald Increases Price Target on Insmed to $54 From $46, Maintains Overweight Rating	23-09-21	MT
Evercore ISI Adjusts Price Target on Insmed to $42 From $32, Maintains Outperform Rating	23-09-07	MT
Mizuho Securities Ups Price Target on Insmed to $33 From $30, Maintains Buy Rating	23-09-06	MT
Guggenheim Initiates Insmed With Buy Rating, $50 Price Target	23-07-26	MT
Mizuho Securities Ups Price Target on Insmed to $30 From $28, Maintains Buy Rating	23-07-26	MT
Cantor Fitzgerald Adjusts Price Target on Insmed to $46 From $49, Maintains Overweight Rating	23-02-24	MT
Barclays Adjusts Insmed Price Target to $35 From $37, Maintains Overweight Rating	23-01-20	MT
Goldman Sachs Cuts Price Target on Insmed to $39 From $44, Keeps Buy Rating	23-01-09	MT
Mizuho Initiates Insmed With Buy Rating, Sets Price Target at $28	22-12-09	MT
Barclays Starts Insmed at Overweight With $37 Price Target	22-12-07	MT
BofA Securities Starts Insmed at Buy With $39 Price Target	22-11-18	MT
Cantor Fitzgerald Adjusts Price Target on Insmed to $49 From $53, Reiterates Overweight Rating	22-10-25	MT
Cowen Adjusts Insmed's Price Target to $53 From $56, Maintains Outperform Rating	22-10-21	MT
Morgan Stanley Adjusts Price Target for Insmed to $41 From $46, Maintains Overweight Rating	22-07-14	MT
Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors	22-07-01	MT
Goldman Sachs Adjusts Insmed's Price Target to $48 from $56, Keeps Buy Rating	22-05-24	MT
Berenberg Bank Adjusts Insmed's Price Target to $46 From $48, Maintains Buy Rating	22-05-09	MT
Goldman Sachs Starts Insmed at Buy With $56 Price Target	22-04-27	MT
SVB Leerink Adjusts Insmed's Price Target to $52 From $57, Maintains Outperform Rating	22-02-22	MT
JPMorgan Starts Insmed at Overweight With $45 Price Target	21-12-06	MT
ANALYST RECOMMENDATIONS : Apple, Boston Beer, Goldman Sachs, Steven Madden, Synthomer...	21-12-06

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.8 USD

Average target price

43.87 USD

Spread / Average Target

+76.88%

High Price Target

55 USD

Spread / Highest target

+121.77%

Low Price Target

35 USD

Spread / Lowest Target

+41.13%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Insmed Incorporated

Barclays
UBS
Wolfe Research
Mizuho Securities
Cantor Fitzgerald
Evercore ISI
Guggenheim
Goldman Sachs
BofA Securities
Cowen
Morgan Stanley
Berenberg Bank
SVB Leerink
JPMorgan Chase
Credit Suisse

Ratings for Insmed Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar